Utility of tocilizumab in autoimmune eye diseases

References

• de Smet Md, Okada AA. Cystoid macular edema in uveitis. Dev Ophthalmol. 2010;47:136–147.
   PubMedGoogle Scholar
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med (Lausanne). 2021;8:695904.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. standardization of uveitis nomenclature for reporting clinical data. results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Touhami S, Diwo E, Sève P, et al.Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 19(5): 477–490. 2019.
   PubMed Web of Science ®Google Scholar
• Gupta Y, Kishore A, Kumari P, et al. Peripheral ulcerative keratitis. Surv Ophthalmol. 2021;66(6):977–998.
   PubMed Web of Science ®Google Scholar
• Dominguez-Casas LC, Sánchez-Bilbao L, Calvo-Río V, et al. Biologic therapy in severe and refractory peripheral ulcerative keratitis (PUK). Multicenter study of 34 patients. Semin Arthritis Rheum. 2020;50(4):608–615.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tooley AA, Mehta VJ, et al. Thyroid Orbitopathy. Int Ophthalmol Clin. 2018;58(2):137–179. Spring.
   PubMedGoogle Scholar
• Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy. Front Endocrinol (Lausanne). 2020;11:615993.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Kahaly GJ, Baldeschi L, et al.EUGOGO †. The 2021 European group on graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 185(4): G43–G67. 2021.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Llorca J, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore). 2000;79(5):283–292.
   PubMed Web of Science ®Google Scholar
• Fein AS, Ko MW. Neuro-Ophthalmologic complications of giant cell arteritis: diagnosis and Treatment. Semin Neurol. 2019;39(6):673–681.
   PubMed Web of Science ®Google Scholar
• Paul S, Mondal GP, Bhattacharyya R, et al. Neuromyelitis optica spectrum disorders. J Neurol Sci. 2021;420:117225.
   PubMed Web of Science ®Google Scholar
• Zahir-Jouzdani F, Atyabi F, Mojtabavi N. Interleukin-6 participation in pathology of ocular diseases. Pathophysiology. 2017;24(3):123–131.
   PubMedGoogle Scholar
• Ebihara N, Matsuda A, Nakamura S, et al. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing. Invest Ophthalmol Vis Sci. 2011;52(12):8549–8557.
   PubMed Web of Science ®Google Scholar
• Lin P. Targeting interleukin-6 for noninfectious uveitis. Clin Ophthalmol. 2015;9:1697–1702.
   PubMed Web of Science ®Google Scholar
• Slowik M, Urbaniak-Kujda D, Bohdanowicz-Pawlak A, et al. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves’ orbitopathy and correlate with disease activity. Endocr Res. 2012;37(2):89–95.
   PubMed Web of Science ®Google Scholar
• Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e841.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. [cited 2022 Jan 9]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125276s131lbl.pdf
   Google Scholar
• Castañeda S, Martínez-Quintanilla D, Martín-Varillas JL, et al. Tocilizumab for the treatment of adult-onset Still’s disease. Expert Opin Biol Ther. 2019;19(4):273–286.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Mayo J, Castañeda S, et al. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Expert Opin Biol Ther. 2020;20(7):717–723.
   PubMed Web of Science ®Google Scholar
• Duarte-Millán MA, Mesa-Plaza N, Guerrero-Santillán M, et al. Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients. J Med Virol. 2021 Nov 29;94:1540–1549.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19(5):382–383.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behçet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol. 2012;22(2):298–302.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, et al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39(6):1294–1295.
   PubMed Web of Science ®Google Scholar
• Oshitari T, Kajita F, Tobe A, et al. Refractory uveitis in patient with Castleman disease successfully treated with tocilizumab. Case Rep Ophthalmol Med. 2012;2012:968180.
   PubMedGoogle Scholar
• Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(11):2627–2632.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22(2):155–157.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, de la Hera D, Beltrán-Catalán E, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S54–57.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75–79.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema. Ophthalmology. 2014;121(12):2380–2386.
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2016;43(12):2183–2188.
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol. 2017;69(3):668–675.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25(2):215–220.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis Study: evaluating the Safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Calvo-Río V, Beltrán E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856–864.
   PubMed Web of Science ®Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema. Retina. 2018;38(7):1361–1370.
   PubMed Web of Science ®Google Scholar
• Vegas-Revenga N, Calvo-Río V, Mesquida M, et al. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85–94.
   PubMed Web of Science ®Google Scholar
• Babu K, Sudheer B, Rao AP. Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema - A case report. Indian J Ophthalmol. 2019;67(6):975–977.
   PubMed Web of Science ®Google Scholar
• Adán A, Moll-Udina A, Ramirez J, et al. Subcutaneous Tocilizumab for Cystoid Macular Edema Secondary to Juvenile Idiopathic Arthritis (JIA)-associated Uveitis: a case report. Ocul Immunol Inflamm. 2021;29(1):6–8.
   PubMed Web of Science ®Google Scholar
• Wennink RAW, Ayuso VK, de Vries LA, et al. Tocilizumab as an effective treatment option in children with refractory intermediate and panuveitis. Ocul Immunol Inflamm. 2021;29(1):21–25.
   PubMed Web of Science ®Google Scholar
• Atienza-Mateo B, Beltrán E, Hernández-Garfella M, et al. Tocilizumab in Behçet’s disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes. Clin Exp Rheumatol. 2021;67(5):37–42. 39 Suppl.
   Google Scholar
• Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181–190.
   PubMed Web of Science ®Google Scholar
• Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9(9):2816.
   PubMed Web of Science ®Google Scholar
• Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: a 9-year single-center experience. J Clin Med. 2021;10(4):706.
   PubMed Web of Science ®Google Scholar
• José J C-M, Rivera-Moscoso R, Jorge A F-R, et al. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a Mexican population. Ann Endocrinol (Paris). 2020;81(2–3):78–82.
   PubMed Web of Science ®Google Scholar
• Bennedjaï A, Bouheraoua N, Gatfossé M, et al. Tocilizumab versus Rituximab in Patients with moderate to severe steroid-resistant Graves’ Orbitopathy. Ocul Immunol Inflamm. 2020 Sep;23:1–6.
   Google Scholar
• Garreta Fontelles G, Sangrador Pelluz C, Macaya Pascual JL. Tocilizumab in Graves ophthalmopathy. Med Clin (Barc). 2020;155(12):561–562.
   PubMed Web of Science ®Google Scholar
• Loricera J, Blanco R, Hernández JL, et al. Tocilizumab in giant cell arteritis: multicenter open-label study of 22 patients. Semin Arthritis Rheum. 2015;44(6):717–723.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317–328.
   PubMed Web of Science ®Google Scholar
• Calderón-Goercke M, Loricera J, Aldasoro V, et al. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. Semin Arthritis Rheum. 2019;49(1):126–135.
   PubMed Web of Science ®Google Scholar
• Prieto Peña D, Martínez-Rodríguez I, Atienza-Mateo B, et al. Evidence for uncoupling of clinical and 18-FDG activity of PET/CT scan improvement in tocilizumab-treated patients with large-vessel giant cell arteritis. Clin Exp Rheumatol. 2021;39(2):69–75. 39 Suppl.
   PubMed Web of Science ®Google Scholar
• Unizony S, McCulley TJ, Spiera R, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021;23(1):8.
   PubMed Web of Science ®Google Scholar
• Amsler J, Kysela I, Tappeiner C, et al. Vision loss in patients with giant cell arteritis treated with tocilizumab. Arthritis Res Ther. 2021;23(1):92.
   PubMed Web of Science ®Google Scholar
• Sanchez-Bilbao L, Loricera J, Aldasoro V, et al. OP0065 Tocilizumab in visual involvement of giant cell arteritis. Multicenter study of 312 patients of clinical practice. Abstract presented as Oral presentation at: European alliance of associations for Rheumatology (EULAR) 2021 virtual congress. Ann Rheum Dis. 2021;80:35–36.
   Google Scholar
• Vionnet J, Buss G, Mayer C, et al. Tocilizumab for giant cell arteritis with corticosteroid-resistant progressive anterior ischemic optic neuropathy. Joint Bone Spine. 2017;84(5):615–619.
   PubMed Web of Science ®Google Scholar
• Svasti-Salee CR, Mollan SP, Morgan AW, et al. Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. BMJ Case Rep. 2019;12(10):e229236.
   PubMedGoogle Scholar
• Khanna RK, Hage R, Lecler A, et al. Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: a case report. J Fr Ophtalmol. 2021 Apr;44(4):481–484.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Qiu W, et al.TANGO Study Investigators. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol. 19(5): 391–401. 2020.
   PubMed Web of Science ®Google Scholar
• Lotan I, McGowan R, Levy M. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: a systematic review of safety and efficacy. Curr Neuropharmacol. 2021;19(2):220–232.
   PubMed Web of Science ®Google Scholar
• Neuromyelitis Optica Study Group (NEMOS), Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-Refractory MOG-IgG-associated disease and neuromyelitis optica Spectrum Disorders. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1100.
   PubMed Web of Science ®Google Scholar
• Herrero-Morant A, Álvarez-Reguera C, Martín-Varillas JL, et al. Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. J Clin Med. 2020;9(8):2608.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis. 2014;73(1):69–74.
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanimura K, Sugimoto T, et al. Musashi Study Investigators. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(3):344–354.
   PubMed Web of Science ®Google Scholar
• Abdallah H, Hsu JC, Lu P, et al. Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459–468.
   PubMed Web of Science ®Google Scholar
• Sánchez-Bilbao L, Loricera J, Baldivieso-Achá J, et al. Effectiveness of Tocilizumab in the visual involvement of Giant Cell Arteritis: multicenter study of 471 patients of clinical practice. poster presented at the American College of Rheumatology (ACR) Convergence 2021. Arthritis Rheumatol. 2021;73(suppl 10):2956.
   Web of Science ®Google Scholar
• Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Wen J, Hu H, Chen M, et al. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: a systematic review. J Immunol Res. 2021;2021:2324400.
   PubMed Web of Science ®Google Scholar